DENVER, March 31, 2022 /CNW/ – Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the “Subscription Agreement“) with a third-party investor (the “Investor“) on March 18, 2022 and the subsequent filing of a shelf prospectus supplement (the…


Previous articleAlbert Labs Files US Provisional Patent Application and Proves Out Consistent and Rapidly Scalable Production of Psilocybe and Other Mycelia
Next articleMydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update